For patients with newly diagnosed multiple myeloma (NDMM) who are transplant ineligible, bortezomib-melphalan-prednisone (VMP) demonstrated superior efficacy based on the VISTA trial. In subsequent trials, twice-weekly bortezomib was limited to the first cycle or completely replaced with once-weekly bortezomib to reduce toxicity. Following a systematic literature review, the efficacy and safety of modified VMP schedules (pooled data from the once-weekly bortezomib VMP arm of the GIMEMA trial and the VMP arm of the ALCYONE trial) were compared to the VISTA schedule using naïve and unanchored matching-adjusted indirect comparison (MAIC). Median progression-free survival was similar between VISTA and modified VMP (20.7 months [95% CI, 18.4–24.3] vs 19.6 months [95% CI, 18.8–21.0]). Peripheral neuropathy was significantly reduced with modified VMP versus VISTA VMP (all grades: naïve, 32.1% vs 46.8% and MAIC, 32.1% vs 46.7%; both p <.0001). These findings support a modified VMP dosing schedule for patients with NDMM who are transplant ineligible.

Additional Metadata
Keywords matching-adjusted indirect comparison, multiple myeloma, VMP
Persistent URL dx.doi.org/10.1080/10428194.2019.1675881, hdl.handle.net/1765/121478
Journal Leukemia and Lymphoma
Citation
Mateos, M.V, San-Miguel, J. (Jesus), Goldschmidt, H, Sonneveld, P, Dimopoulos, M.A, Heeg, B. (Bart), … He, J. (Jianming). (2019). The effects of different schedules of bortezomib, melphalan, and prednisone for patients with newly diagnosed multiple myeloma who are transplant ineligible: a matching-adjusted indirect comparison. Leukemia and Lymphoma. doi:10.1080/10428194.2019.1675881